Adaptive Biotechnologies stock analysis
Want to see ADPT full AI Analyst Report?
Adaptive Biotechnologies (ADPT) Stock Price & Analysis
ADPT Stock Chart & Stats
- Day’s Range
- $28.39 - $29.78
- 52-Week Range
- $12.00 - $32.21
- Previous Close
- $29.48
- Volume
- N/A
- Average Volume (3M)
- 2.16M
- Market Cap
- $4.70B
- Enterprise Value
- $5.52B
- Total Cash (Recent Filing)
- $298.95M
- Total Debt (Recent Filing)
- $408.97M
- Price to Earnings (P/E)
- ―
- Beta
- 1.15
- Next Earnings
- Feb 16, 2027 (Est.)
- EPS Estimate
- -0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Pharma Adoption
Rapid clinical volume growth and a substantially larger pharma backlog indicate expanding use of Adaptive’s testing platform across care and drug development. This supports multi-quarter revenue visibility, strengthens customer relationships, and creates a durable base for continued adoption.
High Margins And Operating Leverage
High gross margins, improving sequencing economics, and higher MRD adjusted EBITDA show that volume growth is translating into operating leverage. Lab efficiencies and scale can support reinvestment in data, automation, and product expansion while improving the path toward sustainable profitability.
Strengthening Clinical Relevance
Explicit inclusion in updated clinical guidelines strengthens clonoSEQ’s role in treatment monitoring and shared decision-making for multiple myeloma. Guideline recognition can support clinician adoption, repeat testing, and reimbursement discussions over the coming quarters.
Bears Say
Elevated Leverage
Debt has risen sharply while equity has declined, leaving Adaptive with less financial flexibility than in prior years. The higher leverage burden increases the importance of continued operating improvement and could constrain investment or amplify pressure if losses persist.
Profitability Remains Inconsistent
Despite a profitable quarter, Adaptive remains structurally loss-making on a trailing basis and does not expect near-term GAAP profitability to persist. Continued operating losses can consume financial resources and delay the point at which growth converts into durable cash earnings.
Reimbursement And ASP Pressure
As physicians monitor patients more frequently, additional tests may fall outside Medicare’s episode structure and reduce realized pricing. This creates a durable reimbursement risk for a growing testing model, potentially limiting revenue per test even as clinical volumes expand.
Adaptive Biotechnologies News
ADPT FAQ
What was Adaptive Biotechnologies’s price range in the past 12 months?
What is Adaptive Biotechnologies’s market cap?
When is Adaptive Biotechnologies’s upcoming earnings report date?
How were Adaptive Biotechnologies’s earnings last quarter?
Is Adaptive Biotechnologies overvalued?
Does Adaptive Biotechnologies pay dividends?
What is Adaptive Biotechnologies’s EPS estimate?
How many shares outstanding does Adaptive Biotechnologies have?
What happened to Adaptive Biotechnologies’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Adaptive Biotechnologies?
What is the TipRanks Smart Score and how is it calculated?
Adaptive Biotechnologies Stock Smart Score
Company Description
Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chad Robins
- Employees
- 624
- Website
- www.adaptivebiotech.com
- Address
- 1165 Eastlake Avenue East, Seattle, WA, 98109, US
Adaptive Biotechnologies (ADPT) Earnings & Revenues
ADPT Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Adaptive reported company-wide profitability ahead of expectations, robust clinical and pharma growth, higher guidance, improving margins, substantial backlog growth and favorable developments for clonoSEQ in multiple myeloma. The main challenges were near-term uncertainty around GAAP profitability, Medicare-related ASP pressure, erroneous CMS pricing data and unpredictable milestone timing, but these issues were outweighed by the reported operating momentum and strategic progress.
View all ADPT earnings summariesADPT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 10 | 0 | 2 |












